CTOs on the Move

Advanced Research Projects Agency for Health

www.arpa-h.gov

 
The Advanced Research Projects Agency for Health (ARPA-H) is committed to solving the most challenging problems in health by developing research programs dedicated to urgency, excellence and honesty. Part of the U.S. Department of Health and Human Services, ARPA-H aims to accelerate breakthroughs that empower every American to realize their full health potential – turning the seemingly impossible to the possible to the actual. The ARPA model is a continuous cycle of planning, implementing, and evaluating, and we`re looking for the best ideas and the brightest minds to carry out each process. We`re committed to diversity in all its forms.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kevin Duvall
ARPA-H Chief Information Officer Profile
Kevin Duvall
Acting Chief Technology Officer and Chief Information Officer Profile

Similar Companies

Appili Therapeutics

Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development.

Eastern Maine Medical Center Federal Credit Union aka EMMC FCU

Eastern Maine Medical Center Federal Credit Union aka EMMC FCU is a Bangor, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palvella Therapeutics

Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.

BioSkryb

Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.

BioNTech SE

At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies worldwide.